Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1273-1281

  Ishibashi, Toru ^a,b   Yano, Yoshitaka ^a   Oguma, Takayoshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b NONE   (Japan)

Author keywords

Area under the plasma concentration time curve (AUC); Nedaplatin; Pharmacodynamics; Pharmacokinetics; Thrombocytopenia; Toxicodynamics

Indexed keywords

ANTINEOPLASTIC AGENT; NEDAPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; JAPAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 17444371285     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Weiss RB and Christian MC: New cisplatin analogues in development. Drugs 46: 360-377, 1993.
2. Kameyama Y, Okazaki N, Nakagawa M, Hikaru K, Masuhisa N and Gemba M: Nephrotoxicity of a new platinum compound, evaluated with rat kidney cortical slices. Toxicol Lett 52: 15-24, 1990.
3. Suzumura S, Kato T, Ueda R and Ohta K: Effect of treatment schedule on antitumor activity of glycolato-O,O' diammineplatinum (II), a new platinum derivatives: comparison with cis-diamminedichloroplatinum (II). Anticancer Res 9: 1083-1088, 1989.
4. Kanzawa F, Matsushima Y, Nakano H, Nakagawa K, Takahashi H, Sasaki Y and Saijyo N: Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Anticancer Res 8: 323-327, 1988.
5. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O and Aso Y: Phase II study of cis-diammine (glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S urological cancer. Cancer Chemother Pharmacol 31: 187-192, 1992.
6. Stephen BD and Bridget AR: Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33: 161-183, 1997.
7. Hartmann JT and Lipp HP: Toxicity of platinum compounds. Expert Opin Pharmacother 4: 889-901, 2003.
8. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D and Sutherland H: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387, 1988.
9. Hryniuk WM, Figueredo A and Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14: 3-11, 1987.
10. Masson E and Zamboni WC: Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 32: 324-343, 1997.
11. Ishibashi T, Yano Y and Oguma T: A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 50: 230-236, 2002.
12. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
13. Ishibashi T, Yano Y and Oguma T: Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 56: 205-213, 2003.
14. Chatelut E, Chevreau C, Brunner V, Martinez M, Houin G, Bugat R and Canal P: A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. Cancer Chemother Pharmacol 35: 391-396, 1995.
15. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H and Watanabe K: Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 42: 307-312, 1998.
16. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA and Beiinen JH: The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 121: 478-486, 1995.
17. Ota K, Oguma T and Shimamura K: Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S. Anticancer Res 14: 1383-1388, 1994.
18. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K and Saijo N: Pharmacokinetics of (glycolato-O,O')-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23: 243-246, 1989.
19. Gormley PE, Bull JM, LeRoy AF and Cysyk R: Kinetics of cis-dichloro diammineplatinum. Clin Pharmacol Ther 25: 351-357, 1979.
20. Takahashi K, Seki T, Nishikawa K, Minamide S, Iwabuchi M, Ono M, Nagamine S and Horinishi H: Antitumour activity and toxicity of serum protein-bound platinum formed from cisplatin, Jpn J Cancer Res 76: 68-74, 1985.
21. Ikeuchi I, Daikatsu K, Fujisaka I and Amano T: Determination of platinum in biological materials by graphite furnace atomic absorption spectrometry [abstract]. Iyakuhin Kenkyu 21: 1082-1087, 1990.
22. Beal SL and Sheiner LB: NONMEM: user's guide part I-VIII. University of California at San Francisco, San Francisco, 1998.
23. The revised common toxicity criteria: Version 2.0 CTEP Website. http://ctep.info.nih.gov.
24. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W and Curran W: Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Rad Oncol Biol Phys 47: 13-47, 2000.
25. Sasaki Y, Fukuda M, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Yamada K, Kojima A, Nakagawa K, Ohmori T and Saijo N: Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-o,o')-diammine platinum (II) (NSC 375101D). Jpn J Cancer Res 81: 196-200, 1990.
26. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J and Egorin MJ: Phase 1 trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17: 676-684, 1999.
27. Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Heimerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH and ten Bokkel Huinink WW: Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15: 1953-1964, 1997.
28. Suzuki K, Matsumoto K, Hashimoto K, Kurokawa K, Jinbo S, Suzuki T, Imai K, Yamanaka H, Kawashima K and Takahashi H: Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression. Hinyokika Kiyo 41: 775-780, 1995.
29. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A and Saijo N: Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 51: 1472-1477, 1991.
30. Newell DR, Pearson AD, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR and Stevens MC: Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 11: 2314-2323, 1993.
31. Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH and ten Bokkel Huinink WW: Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15: 1953-1964, 1997.
32. Akaike H: Stochastic theory of minimal realization. I.E.E.E. Trans Automat Contr 19: 716-723, 1974.
33. Yamaoka K, Nakagawa T and Uno T: Application of Akaike's information criterion (AIC) in the evaluation on linear pharmacokinetic equations. J Pharm Sci 6: 165-175, 1978.
34. Sheiner LB and Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512, 1981.
35. Wold S: Cross-validatory estimation of the number of components in factor and principal component models. Technometrics 20: 397-406, 1978.